The global market for Diabetic Kidney Diseases was valued at US$2.9 Billion in 2024 and is projected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Diabetic Kidney Diseases market.
Improved clinical guidelines are promoting earlier screening and multifactorial intervention, with an emphasis on not just glycemic control but also blood pressure management, proteinuria reduction, and cardiovascular risk minimization. Multidisciplinary management models involving nephrologists, endocrinologists, and cardiologists are reshaping treatment pathways to delay or prevent progression to dialysis or transplantation.
Combination therapies using GLP-1 receptor agonists, SGLT2 inhibitors, and novel MRAs are becoming increasingly common in personalized DKD management. Additionally, anti-inflammatory and anti-fibrotic agents targeting the molecular mechanisms of renal injury are entering the late stages of clinical development. Diagnostic advancements like urine biomarkers and eGFR estimation tools are enabling earlier and more accurate disease staging.
The market is heavily dominated by pharmaceutical companies offering integrated cardiorenal solutions, while diagnostic players are providing advanced testing panels for proteinuria, microalbuminuria, and serum creatinine. Key stakeholders also include public health agencies promoting kidney screening programs and value-based care models incentivizing long-term renal preservation.
Increased awareness of DKD’s link to cardiovascular outcomes is enhancing diagnosis and treatment rates. Government health systems and private insurers are recognizing the cost savings of early intervention, thereby incentivizing use of advanced therapies. Together, these trends are transforming DKD from a poorly managed diabetes complication into a focal point of preventive nephrology.
Segments: Drug Class (Angiotensin Receptor Blockers, Calcium Channel Blockers, Antioxidant Inflammation Modulator, Angiotensin-Converting Enzyme Inhibitors, Other Drug Classes); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Diabetic Kidney Diseases Market - Key Trends & Drivers Summarized
Can Therapeutics Slow Down the Progression of Renal Decline?
Diabetic kidney disease (DKD), or diabetic nephropathy, is one of the most serious long-term complications of both Type 1 and Type 2 diabetes, accounting for nearly 50% of end-stage renal disease (ESRD) cases worldwide. With global diabetes prevalence rising, DKD has emerged as a significant healthcare burden, particularly in developed and aging populations. One of the most significant trends in this market is the shift from renin-angiotensin-aldosterone system (RAAS) inhibitors to newer classes of nephroprotective agents, including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and GLP-1 receptor agonists.Improved clinical guidelines are promoting earlier screening and multifactorial intervention, with an emphasis on not just glycemic control but also blood pressure management, proteinuria reduction, and cardiovascular risk minimization. Multidisciplinary management models involving nephrologists, endocrinologists, and cardiologists are reshaping treatment pathways to delay or prevent progression to dialysis or transplantation.
Why Is Drug Development Pivotal in Slowing DKD Progression?
Traditional therapies such as ACE inhibitors and ARBs have shown limited efficacy in halting disease progression, especially in advanced stages. The approval of SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) has been a game-changer, offering significant renal protection alongside cardiovascular benefits - even in patients without diabetes. Similarly, finerenone, a non-steroidal MRA, is demonstrating promising outcomes in reducing albuminuria and eGFR decline with a lower hyperkalemia risk.Combination therapies using GLP-1 receptor agonists, SGLT2 inhibitors, and novel MRAs are becoming increasingly common in personalized DKD management. Additionally, anti-inflammatory and anti-fibrotic agents targeting the molecular mechanisms of renal injury are entering the late stages of clinical development. Diagnostic advancements like urine biomarkers and eGFR estimation tools are enabling earlier and more accurate disease staging.
Where Is the Market Expanding and Who Are the Target Populations?
The DKD market is growing fastest in regions with high diabetes prevalence and rapidly aging populations, including North America, China, and Western Europe. India and parts of Latin America are also emerging as hotspots due to high levels of undiagnosed diabetes and poor long-term glycemic control.The market is heavily dominated by pharmaceutical companies offering integrated cardiorenal solutions, while diagnostic players are providing advanced testing panels for proteinuria, microalbuminuria, and serum creatinine. Key stakeholders also include public health agencies promoting kidney screening programs and value-based care models incentivizing long-term renal preservation.
What’s Driving Growth in the Diabetic Kidney Diseases Market?
The growth in the diabetic kidney diseases market is driven by multiple factors including rising global diabetes incidence, improved drug therapies, and early diagnostic capabilities. The introduction of SGLT2 inhibitors and non-steroidal MRAs is expanding treatment options with proven renal protection benefits. Growing investment in CKD clinical research and the emergence of novel anti-inflammatory agents are also fueling the innovation pipeline.Increased awareness of DKD’s link to cardiovascular outcomes is enhancing diagnosis and treatment rates. Government health systems and private insurers are recognizing the cost savings of early intervention, thereby incentivizing use of advanced therapies. Together, these trends are transforming DKD from a poorly managed diabetes complication into a focal point of preventive nephrology.
Report Scope
The report analyzes the Diabetic Kidney Diseases market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Drug Class (Angiotensin Receptor Blockers, Calcium Channel Blockers, Antioxidant Inflammation Modulator, Angiotensin-Converting Enzyme Inhibitors, Other Drug Classes); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Angiotensin Receptor Blockers segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of a 2.8%. The Calcium Channel Blockers segment is also set to grow at 4.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $800.5 Million in 2024, and China, forecasted to grow at an impressive 6.2% CAGR to reach $709.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Diabetic Kidney Diseases Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Diabetic Kidney Diseases Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Diabetic Kidney Diseases Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim GmbH and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Diabetic Kidney Diseases market report include:
- AbbVie Inc.
- AstraZeneca plc
- Aurobindo Pharma Limited
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- CSL Vifor
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd
- Eli Lilly and Company
- Endo International plc
- F. Hoffmann-La Roche Ltd
- Fresenius Medical Care AG & Co. KGaA
- GlaxoSmithKline plc
- Inversago Pharma Inc.
- Johnson & Johnson
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- AstraZeneca plc
- Aurobindo Pharma Limited
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- CSL Vifor
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd
- Eli Lilly and Company
- Endo International plc
- F. Hoffmann-La Roche Ltd
- Fresenius Medical Care AG & Co. KGaA
- GlaxoSmithKline plc
- Inversago Pharma Inc.
- Johnson & Johnson
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 372 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.9 Billion |
| Forecasted Market Value ( USD | $ 3.6 Billion |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
